Lexington, MA – According to filings with the U.S. Securities and Exchange Commission, Hemanext is raising $59,475,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Martin Cannon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Hemanext
Hemanext is a medical technology company with headquarters and R&D Center of Excellence in Lexington MA, and manufacturing operations in Avon MA. Hemanext is committing its resources to the continuing effort of the transfusion medicine community to save lives and improve patient outcomes. Our distinctive focus is on innovations in systems enabling blood collection, processing, storage and transfusion that will promote dramatic improvements in transfusion therapies. Hemanext ONE: An innovative storage system for red blood cells. This technology has been developed with funding from private investors as well as grants and development contracts from the National Institutes of Health.

To learn more about Hemanext, visit http://www.hemanext.com/

Contact:
Martin Cannon, President and Chief Executive Officer
781-301-7474
https://www.linkedin.com/in/martincannon1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved